These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26938643)

  • 41. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.
    Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Yedilbayev A; Rich ML; Mukherjee JS; Furin JJ; Atwood S; Farmer PE; Keshavjee S
    Int J Tuberc Lung Dis; 2007 Dec; 11(12):1314-20. PubMed ID: 18034952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
    Aibana O; Bachmaha M; Krasiuk V; Rybak N; Flanigan TP; Petrenko V; Murray MB
    BMC Infect Dis; 2017 Feb; 17(1):129. PubMed ID: 28173763
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment outcomes among multidrug-resistant TB patients in Bahawal Victoria Hospital, Bahawalpur, Pakistan: a retrospective record review.
    Atif M; Ahmad W; Ahmad N; Malik I; Sarwar S
    Trans R Soc Trop Med Hyg; 2020 Oct; 114(10):733-741. PubMed ID: 32556195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China.
    Han XQ; Pang Y; Ma Y; Liu YH; Guo R; Shu W; Huang XR; Ge QP; DU J; Gao WW
    Biomed Environ Sci; 2017 Feb; 30(2):139-142. PubMed ID: 28292352
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk Factors for Multidrug-resistant Tuberculosis.
    Rumende CM
    Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.
    Piparva KG; Jansari G; Singh AP
    Perspect Clin Res; 2018; 9(4):165-169. PubMed ID: 30319946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?
    Balabanova Y; Ignatyeva O; Fiebig L; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F
    Thorax; 2016 Sep; 71(9):854-61. PubMed ID: 27012887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan.
    Khan FU; Khan A; Khan FU; Hayat K; Rehman AU; Chang J; Khalid W; Noor S; Khan A; Fang Y
    Front Pharmacol; 2022; 13():876955. PubMed ID: 35656303
    [No Abstract]   [Full Text] [Related]  

  • 52. Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan.
    Massud A; Khan AH; Syed Sulaiman SA; Ahmad N; Shafqat M; Ming LC
    PLoS One; 2023; 18(8):e0287966. PubMed ID: 37561810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
    Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
    Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
    Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
    BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
    Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
    PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
    Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
    J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006.
    Masjedi MR; Tabarsi P; Chitsaz E; Baghaei P; Mirsaeidi M; Amiri MV; Farnia P; Javanmard P; Mansouri D; Velayati AA
    Int J Tuberc Lung Dis; 2008 Jul; 12(7):750-5. PubMed ID: 18544199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment Outcomes and Adverse Events from a Standardized Multidrug-Resistant Tuberculosis Regimen in a Rural Setting in Angola.
    Aznar ML; Rando Segura A; Moreno MM; Espasa M; Sulleiro E; Bocanegra C; Gil Olivas E; Eugénio AN; Zacarias A; Katimba D; Gabriel E; Mendioroz J; López García MT; Pumarola T; Tórtola MT; Molina I
    Am J Trop Med Hyg; 2019 Sep; 101(3):502-509. PubMed ID: 31333153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multidrug-resistant tuberculosis in the Northern Territory: A 10-year retrospective case series.
    Judge D; Krause V
    Commun Dis Intell Q Rep; 2016 Sep; 40(3):E334-E339. PubMed ID: 28278406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.